Mutant of cyclodextrin glycosyltransferase
The present invention discloses a mutant of cyclodextrin glycosyltransferase and belongs to the fields of gene engineering and enzyme engineering. According to the present invention, a mutant having higher disproportionation activity of cyclodextrin glycosyltransferase is obtained by mutating the cyclodextrin glycosyltransferase. The disproportionation activity of enzymes of mutants V6D, S90G, T168A, T171A, T383A, G608A, and V6D/S90G/T168A/T171A/T383A/G608A, is respectively 1.89 times, 1.21 times, 1.21 times, 1.22 times, 1.32 times, 2.03 times, and 3.16 times that of the wild type enzyme in shake flask fermentations.
1. A mutant of cyclodextrin glycosyltransferase, consisting of one of the following mutations:
(a) a mutation of the valine (V) at site 6 to aspartic acid (V6D) in the cyclodextrin glycosyltransferase with the amino acid sequence set forth in SEQ ID NO: 2;
(b) a mutation of the threonine (T) at site 171 to alanine (T171A) in the cyclodextrin glycosyltransferase with the amino acid sequence set forth in SEQ ID NO: 2;
(c) a mutation of the threonine (T) at site 383 to alanine (T383A) in the cyclodextrin glycosyltransferase with the amino acid sequence set forth in SEQ ID NO: 2;
(d) a mutation of the glycine (G) at site 608 to alanine (G608A) in the cyclodextrin glycosyltransferase with the amino acid sequence set forth in SEQ ID NO: 2; or
(e) a mutation of the valine (V) at site 6 to the aspartic acid, a mutation of the serine (S) at site 90 to glycine, a mutation of the threonine (T) at site 168 to alanine, a mutation of the threonine (T) at site 171 to alanine, a mutation of the threonine (T) at site 383 to alanine, and a mutation of the glycine (G) at site 608 to alanine,
wherein the cyclodextrin glycosyltransferase is derived from Bacillus circulans , and
wherein the amino acid sequence of the cyclodextrin glycosyltransferase derived from Bacillus circulans is set forth in SEQ ID NO: 2.
2. The mutant cyclodextrin glycosyltransferase of claim 1 , wherein the mutation is a mutation of the valine (V) at site 6 to aspartic acid (V6D) in the cyclodextrin glycosyltransferase with the amino acid sequence set forth in SEQ ID NO: 2.
3. The mutant cyclodextrin glycosyltransferase of claim 1 , wherein the mutation is a mutation of the threonine (T) at site 171 to alanine (T171A) in the cyclodextrin glycosyltransferase with the amino acid sequence set forth in SEQ ID NO: 2.
4. The mutant cyclodextrin glycosyltransferase of claim 1 , wherein the mutation is a mutation of the threonine (T) at site 383 to alanine (T383A) in the cyclodextrin glycosyltransferase with the amino acid sequence set forth in SEQ ID NO: 2.
5. The mutant cyclodextrin glycosyltransferase of claim 1 , wherein the mutation is a mutation of the glycine (G) at site 608 to alanine (G608A) in the cyclodextrin glycosyltransferase with the amino acid sequence set forth in SEQ ID NO: 2.
6. The mutant cyclodextrin glycosyltransferase of claim 1 , wherein the mutation is a mutation of the valine (V) at site 6 to the aspartic acid, a mutation of the serine (S) at site 90 to glycine, a mutation of the threonine (T) at site 168 to alanine, a mutation of the threonine (T) at site 171 to alanine, a mutation of the threonine (T) at site 383 to alanine, and a mutation of the glycine (G) at site 608 to alanine.
7. A method for constructing the cyclodextrin glycosyltransferase mutant of claim 1 , comprising:
(1) designing a site-directed mutagenesis mutant primer according to the determined mutation site, and performing site-directed mutagenesis using a vector carrying a cyclodextrin glycosyltransferase gene as a template; constructing a plasmid vector comprising a gene encoding the mutant;
(2) transforming the mutant plasmid vector into a host cell;
(3) selecting positive clones for fermentation culture, and centrifuging the supernatant to obtain a crude enzyme solution of the cyclodextrin glycosyltransferase mutant.
8. The method of claim 7 , wherein the plasmid vector is any one of pUC series, pET series, or pGEX.
9. The method of claim 7 , wherein the plasmid vector is cgt/pET20b(+).
10. The method of claim 7 , wherein the host cell is a bacterial or fungal cell.